-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。DCF分析に基づき、有形帳簿価額に対するプレミアムを前提として、12ヶ月目標株価を8ドルから5ドルに引き下げます。販売台数の減少とコストの上昇を前提とした調整後EBITDA予想は、PSNYの販売台数が2026年にわずか3%しか増加しないと想定しているため、小幅に下方修正します。PSNYの第4四半期純損失は7億9,900万ドルで、市場予想の4億5,200万ドルを大きく下回りましたが、2024年第4四半期の11億8,300万ドルの損失からは改善しました。さらに重要な点として、今後の見通しについて、経営陣は慎重なガイダンスを示しています。2025年の販売台数は60,119台で、世界全体の小売販売台数は10%台前半の増加を見込んでいます。しかし、世界のEV販売台数の伸びが鈍化していることを考慮すると、このガイダンスはやや楽観的すぎる可能性が高いと考えられます。いずれにせよ、12月の1対30の株式併合にもかかわらず、株価は最近好調に推移しており、ボルボ/吉利汽車ホールディングス(175 HK 25 ****)などからの追加的な支援がない限り、キャッシュフローの減少は高止まりし、リストラのリスクが高まると予想されます。2025年にマイナス13億7000万ドルのフリーキャッシュフローを計上した後、2026年にはマイナス12億ドルになると予測しています。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.